Nastassia Samal/iStock via Getty Images By Brian Levitt, Chief Global Market Strategist and Head of Strategy & Insights For as long as I can remember, I have been a FOMO guy. A “fear of missing out” has long shaped how I spend my time. It has its downsides, including occasional bouts of exhaustion, but I wouldn’t trade it. I genuinely cannot relate to the mindset of being comfortable standing on t...
Nastassia Samal/iStock via Getty Images By Brian Levitt, Chief Global Market Strategist and Head of Strategy & Insights For as long as I can remember, I have been a FOMO guy. A “fear of missing out” has long shaped how I spend my time. It has its downsides, including occasional bouts of exhaustion, but I wouldn’t trade it. I genuinely cannot relate to the mindset of being comfortable standing on the sidelines while things are happening. I admitted as much on television in 2022. Markets were on their way to being down 20% during an inflation scare and the beginning of the Russia-Ukraine war. 1 When asked whether it was time to derisk portfolios, I responded that I was a FOMO guy who didn’t want to miss a market advance. It felt like a throwaway comment in the moment. Four years later, the same hosts still ask me if I’m still a FOMO guy. I never expected to be on television at all, let alone to have a self-admitted personality trait turn into a nickname. Brian Levitt, the FOMO guy, doesn’t quite roll off the tongue like Bill Nye, the Science Guy, but I wear it happily. That instinct served me well again this April. Markets climbed back to all-time highs as the market assigned a growing probability of an end to the conflict with Iran. 2 It was another reminder that markets often move forward while the world languishes over the news flow. Fear of missing out isn’t about ignoring risk. It’s about recognizing how costly it can be to wait for the clarity that never fully arrives. It may be confirmation bias but … … markets have historically tended to perform well in the 12 months following the onset of a geopolitical conflict , provided the economy was on a solid footing beforehand. 3 The notable exceptions have been the 1973 Yom Kippur War and the 2022 Russia-Ukraine war, when stock markets struggled in the year that followed, when inflation was already running above 7% before they began. 4 The Middle East conflict started with the global economy still expanding 5 and inf...
(RTTNews) - UPM-Kymmene Oyj (UPMKF, RPL.F), a Finnish material solutions company, reported Wednesday higher profit in its first quarter, despite weak sales.
(RTTNews) - UPM-Kymmene Oyj (UPMKF, RPL.F), a Finnish material solutions company, reported Wednesday higher profit in its first quarter, despite weak sales.
Aena SME S.A. ADR press release ( ANYYY ): Q1 net profit of 329.4M euros in the first quarter of 2026, compared to 301.3M euros in the same period last year. Total revenue exceeds 1,479.9 million euros, 11.6% up on the first three months of 2025 The gross operating profit EBITDA stood at 661.1 million euros, with a margin of 44.7%. This figure represents a growth of 2.7% compared to 2025 (643.6 mi...
Aena SME S.A. ADR press release ( ANYYY ): Q1 net profit of 329.4M euros in the first quarter of 2026, compared to 301.3M euros in the same period last year. Total revenue exceeds 1,479.9 million euros, 11.6% up on the first three months of 2025 The gross operating profit EBITDA stood at 661.1 million euros, with a margin of 44.7%. This figure represents a growth of 2.7% compared to 2025 (643.6 million). More on Aena SME S.A. ADR Aena SME S.A. ADR (ANYYY) Shareholder/Analyst Call Prepared Remarks Transcript Aena SME S.A. ADR 2025 Q4 - Results - Earnings Call Presentation Aena SME S.A. ADR (ANYYY) Q4 2025 Earnings Call Transcript Aena SME S.A. ADR reports FY results Seeking Alpha’s Quant Rating on Aena SME S.A. ADR
A South Korean appeal court increased the sentence of jailed former president Yoon Suk-yeol on Wednesday to seven years for obstructing justice, up from five years. A lower court had handed Yoon the initial sentence in January after he was found to have used presidential security agents to block his own arrest. Both Yoon and the prosecution lodged appeals. He argued that the arrest warrants agains...
A South Korean appeal court increased the sentence of jailed former president Yoon Suk-yeol on Wednesday to seven years for obstructing justice, up from five years. A lower court had handed Yoon the initial sentence in January after he was found to have used presidential security agents to block his own arrest. Both Yoon and the prosecution lodged appeals. He argued that the arrest warrants against him were based on an “unlawful investigation”, while special prosecutors said his punishment...
Homayoun Falakshahi, head of crude oil analysis at Kpler, discusses energy markets as investors focus on the next step for peace talks between the US and Iran. He tells Bloomberg Television that should the US manage to sustain its blockade of the Strait of Hormuz for another two months, "Iran's oil revenues will drop to zero." Falakshahi also warns that should the waterway remain closed for anothe...
Homayoun Falakshahi, head of crude oil analysis at Kpler, discusses energy markets as investors focus on the next step for peace talks between the US and Iran. He tells Bloomberg Television that should the US manage to sustain its blockade of the Strait of Hormuz for another two months, "Iran's oil revenues will drop to zero." Falakshahi also warns that should the waterway remain closed for another two months, prices for oil could go back to "roughly 120, 125 [dollars a barrel] for Brent." (Source: Bloomberg)
Morning, I’m Louise Moon from Bloomberg UK’s breaking news team, bringing you up to speed on today’s top business stories. Strong sales of cancer medicines are proving a boon to the two largest London-listed drugmakers: AstraZeneca and GSK . The former has built itself up as an oncology powerhouse under CEO Pascal Soriot, and it’s paying off. Existing blockbusters and a pipeline of newer medicines...
Morning, I’m Louise Moon from Bloomberg UK’s breaking news team, bringing you up to speed on today’s top business stories. Strong sales of cancer medicines are proving a boon to the two largest London-listed drugmakers: AstraZeneca and GSK . The former has built itself up as an oncology powerhouse under CEO Pascal Soriot, and it’s paying off. Existing blockbusters and a pipeline of newer medicines have helped reassure investors that the once ambitious target of $80 billion in annual revenue by 2030 is achievable. First quarter profit grew more than expected and Astra maintained guidance , though shares were little changed. Other drugs are still lagging. It’s a similar story for GSK. Profits were better than expected , helped by cancer, HIV and immune diseases medicines, but shares inched lower. New CEO Luke Miels has a big task to overhaul the company, which has long struggled to allay investor concerns over a dearth of promising new drugs. While oncology is particularly strong, there’s work to be done. What’s your take? Ping me on X , LinkedIn or drop me an email at lmoon13@bloomberg.net. Oh, and do subscribe to Bloomberg.com for unlimited access to trusted business journalism on the UK, and beyond. What We’re Watching Carmaker Aston Martin posted yet another loss as billionaire owner Lawrence Stroll’s turnaround struggles to get out of first gear. It’s been relying on capital raises led by Stroll’s consortium, including another £50 million facility today. Lloyds ’ profit rose 33% , with CEO Charlie Nunn saying it was “resilient” amid current uncertainties. As Britain’s biggest mortgage lender, the bank’s fortunes are more tied to consumer health. More from my colleague Kit below. Weak demand for cold and flu drugs hit sales at Panadol maker Haleon , echoing rival Reckitt last week. A wary shopper adds to higher energy costs and supply chain disruptions. Shares fell 1.2%. The UK risks slipping into recession later this year and the BOE could be forced to aggressive...
(RTTNews) - Sandoz (SDZ.SW) reported first quarter net sales of $2.76 billion compared to $2.48 billion, prior year. Sandoz said its performance was in line with company expectations. The company confirmed its guidance for 2026.
(RTTNews) - Sandoz (SDZ.SW) reported first quarter net sales of $2.76 billion compared to $2.48 billion, prior year. Sandoz said its performance was in line with company expectations. The company confirmed its guidance for 2026.